Clinical Evaluation Of Irbesartan And Bisoprolol In The Treatment Of Chronic Heart Failure
Recently, the Second People's Hospital of Yunnan Province, Jiang Xue and other studies irbesartan and bisoprolol in the treatment of chronic heart failure clinical evaluation, the study found that, in the conventional treatment measures based on the combination of irbesartan and pesosone Lorol in the treatment of chronic heart failure can significantly improve the patient's cardiac function, reduce serum hs-CRP, BNP levels, the clinical effect is obvious. This article was published in "2016 China Prescription Drugs".
This study aimed to observe the clinical efficacy of irbesartan and bisoprolol in the treatment of chronic heart failure (CHF).
The researchers selected 96 patients with CHF who were admitted from July 2012 to December 2014 and were randomly divided into observation group and control group with 48 cases in each group. The control group was treated with irbesartan on the basis of routine therapy such as oxygen, diuretic and cardiac therapy. The observation group was treated with irbesartan and bisoprolol on the basis of routine treatment. After 8 weeks of treatment, the clinical curative effect, changes of cardiac function before and after treatment, serum hs-CRP and BNP levels were compared.
The results showed that compared with the control group, the total effective rate in the observation group was significantly higher than that in the control group (91.67% vs. 75.00%, P <0.05). After treatment, the mean diameter of the left ventricular end-systolic (LVEDD), left ventricular end diastolic diameter (LVEDD) was significantly lower than before treatment, left ventricular ejection fraction (LVEF) was significantly higher than before treatment (P <0.05); LVESD, LVEDD and LVEF improved in the observation group than in the control group After treatment, the relevant indexes were more obvious, the differences were statistically significant (P <0.05). The levels of hs-CRP and BNP in the observation group were significantly lower than those in the control group after treatment (P <0.05).